HLA-C and neoplasm: CAR-T cells activate anti-tumor immunity by expressing chimeric antigen receptor (CAR) on the surface of autologous or allogeneic T cells, targeting tumor-associated antigens and binding, activating T cells and releasing relevant cytokines without relying on MHC molecules for antigen presentation and co-stimulatory molecules (58).